LIN28B is a post-transcriptional regulator of Wnt signalling in myeloid leukemia cells and dual targeting promotes cytotoxicity

LIN28B interacts with β-catenin and regulates Wnt signaling through post-transcriptional modulation in myeloid leukemia cells.

• Why it matters: Wnt/β-catenin signaling is often dysregulated in hematological malignancies, but effective targeted therapies are lacking, highlighting the need for new therapeutic strategies.
• What they did: The study examined the molecular interaction between LIN28B and β-catenin in myeloid and lymphoid cell lines, primary human HSCs, and analyzed the effects of dual pharmacological targeting on cell viability, using techniques like RNA and miRNA sequencing.
• The result: Dual targeting of LIN28B and β-catenin reduced myeloid cell viability and revealed a potential novel therapeutic axis for rare myeloid neoplasms with β-catenin dysregulation and LIN28B reactivation.